Full Breakdown
FDA's Rejection and Subsequent Review of Moderna's mRNA Flu Vaccine
2/18/2026, 3:08:42 AM
Overview of the Core Event
The U.S. Food and Drug Administration (FDA) initially rejected Moderna’s request to review its mRNA flu vaccine, despite evidence from late-stage trials indicating the vaccine's safety and efficacy. This decision has raised concerns regarding the FDA's approach to vaccine approvals and the implications for public health.
Timeline of Events
- April 2024: Moderna begins discussions with the FDA regarding the study plan for its mRNA flu vaccine.
- February 2026: The FDA announces its rejection of Moderna's application for the mRNA flu vaccine, stating concerns over the control product used in trials.
- February 11, 2026: The FDA backtracks on its initial refusal, suggesting a potential future approval of the vaccine.
Key Figures Involved
- Dr. Vinay Prasad: The top vaccine regulator at the FDA who made the decision to block the review of Moderna's application.
- Dr. Marty Makary: The FDA commissioner who defended the agency's decision and indicated that the agency might eventually approve the vaccine.
- Andrew Nixon: A spokesman for the Department of Health and Human Services who provided context on the FDA's concerns regarding the trial design.
Official Statements & Responses
Following the rejection, Dr. Marty Makary characterized the FDA's decision as part of an ongoing dialogue with drug manufacturers. He emphasized that the agency would continue to collaborate with Moderna. Andrew Nixon highlighted that the FDA had requested a high-dose flu vaccine as a control for older participants, which Moderna did not use, leading to concerns about increased risks.
Criticism & Opposition
The rejection of Moderna's application has drawn criticism from various stakeholders, including public health experts who are concerned about the implications for vaccine innovation and public trust in the FDA. Critics argue that the decision reflects a troubling trend in regulatory practices that could hinder timely access to potentially life-saving vaccines.
Conflicting Reports & Gaps
There are discrepancies regarding the rationale behind the FDA's initial rejection. While the FDA cited concerns over the control product used in trials, Moderna has disputed this account, claiming that the agency had previously agreed to the study design involving GSK's Fluarix vaccine. This conflict raises questions about the communication and decision-making processes within the FDA.
What's Next
As the FDA has indicated a willingness to reconsider its stance on Moderna's mRNA flu vaccine, further discussions and evaluations are expected. The agency's future actions will be closely monitored by both the public and industry stakeholders, as they could set important precedents for vaccine approvals moving forward.
Verbatim Quotes
- “part of a conversation that occurs with all drug makers” — Dr. Marty Makary, FDA Commissioner
- “We are having trouble retrieving the article content.” — Andrew Nixon, Spokesman for the Department of Health and Human Services
